Unsupervised immunophenotypic profiling of chronic lymphocytic leukemia

Proteomics and functional genomics have revolutionized approaches to disease classification. Like proteomics, flow cytometry (FCM) assesses concurrent expression of many proteins, with the advantage of using intact cells that may be differentially selected during analysis. However, FCM has generally been used for incremental marker validation or construction of predictive models based on known patterns, rather than as a tool for unsupervised class discovery. We undertook a retrospective analysis of clinical FCM data to assess the feasibility of a cell‐based proteomic approach to FCM by unsupervised cluster analysis.

[1]  Bjarte Dysvik,et al.  Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles , 2002, International journal of cancer.

[2]  Paul R. Yarnold,et al.  Reading and understanding MORE multivariate statistics. , 2000 .

[3]  A. Szczepek,et al.  A cholesterol-dependent CD20 epitope detected by the FMC7 antibody , 2003, Leukemia.

[4]  T. Sellers,et al.  Review of proteomics with applications to genetic epidemiology , 2003, Genetic epidemiology.

[5]  S. Proctor,et al.  The Prognostic Value of CD38 Expression and its Quantification in B Cell Chronic Lymphocytic Leukemia (B-CLL) , 2004, Leukemia & lymphoma.

[6]  M. Tyers,et al.  From genomics to proteomics , 2003, Nature.

[7]  M. Hurme,et al.  Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities , 2002, Leukemia.

[8]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[9]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Yuhai Tu,et al.  Identification of a global gene expression signature of B-chronic lymphocytic leukemia. , 2003, Molecular cancer research : MCR.

[11]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[12]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[13]  Yvan Cornet,et al.  Immunophenotypic clustering of myelodysplastic syndromes. , 2002, Blood.

[14]  S. Hanash.  Disease proteomics : Proteomics , 2003 .

[15]  J. Edwards,et al.  Prospects for B-cell-targeted therapy in autoimmune disease. , 2005, Rheumatology.

[16]  P. Sopp.  Cluster analysis. , 1996, Veterinary immunology and immunopathology.

[17]  D. Huhn,et al.  Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. , 2001, Cytometry.

[18]  K. Do,et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[19]  M. Dwek,et al.  Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues , 2003, British Journal of Cancer.